DT-101

Phase 2Small molecule

DDraig Therapeutics Ltd

DT-101 is one of 6 small molecule programs targeting Major Depressive Disorder (MDD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive Disorder (MDD)Recruiting

Major Depressive Disorder (MDD)Phase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Major Depressive Disorder (MDD)

#DrugCompanyPhaseTrials

ONO-1110

Ono Pharmaceutical Co. Ltd

Phase 2

1 2

CYB003

CCybin IRL Limited

Phase 3

1 3

SPT-300

SSeaport Therapeutics

Phase 2

2 4

ACP-211

AACADIA Pharmaceuticals Inc.

Phase 2

1 5

CLE-100

CClexio Biosciences Ltd.

Phase 2

1 6

DT-101

DDraig Therapeutics Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Major Depressive Disorder (MDD)

NCT07300969

Clinical

Trials by Indication[1]

Major Depressive Disorder (MDD)1 trial

A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)

Recruiting·DDraig Therapeutics Ltd·Phase 2·NCT07300969·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Draig Therapeutics Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDraig Therapeutics Ltd

DT-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Major Depressive Disorder (MDD)1 trial

References

Drug Info

Quick Facts

Related News